9,388 results match your criteria Ovarian Cancer* Obstetrics and Gynecology


Novel triazole analogs of apigenin-7-methyl ether exhibit potent antitumor activity against ovarian carcinoma cells via the induction of mitochondrial-mediated apoptosis.

Exp Ther Med 2019 Mar 28;17(3):1670-1676. Epub 2018 Dec 28.

Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.

Ovarian cancer is one of the main causes of cancer-associated mortality across the world. Currently, ovarian cancer is mainly treated with chemotherapy. However, ovarian cancer is detected at advanced stages and chemotherapy has numerous side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364180PMC

Macrophage ERα promoted invasion of endometrial cancer cell by mTOR/KIF5B -mediated epithelial to mesenchymal transition.

Immunol Cell Biol 2019 Feb 18. Epub 2019 Feb 18.

Institute of Basic Medical Sciences and Key Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Tumor associated macrophages (TAMs) exert tumor-promoting effects. There have been reports that Estrogen receptors (ERs) are expressed on the infiltrating macrophages of endometriosis, ovarian cancer and lung cancer. However, the role of ERs in macrophages is not well characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imcb.12245DOI Listing
February 2019

PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.

Cell Death Dis 2019 Feb 18;10(3):166. Epub 2019 Feb 18.

Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 250012, Jinan, China.

High-grade serous ovarian carcinoma (HGSOC) is the most lethal type of gynecologic malignancy. Chemoresistance is the main reason for the poor prognosis of HGSOC. PDZ-binding kinase (PBK) promotes the malignant progression of various carcinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1415-6DOI Listing
February 2019

Endometriosis-associated ovarian cancer: What have we learned so far?

Clin Chim Acta 2019 Feb 15. Epub 2019 Feb 15.

Division of Laboratory Medicine, Asia University Hospital, Asia University, Taichung, Taiwan; Deparment of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan; Deparment of Post-Baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan; Deparment of Nursing, Asia University, Taichung, Taiwan. Electronic address:

Endometriosis is defined as the presence of ectopic endometrial tissue outside of the uterine cavity, most commonly in the ovaries and peritoneum. It is a complex disease that is influenced by multiple factors. It is also a common gynecological disorder and affects approximately 10-15% of all women of reproductive age. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00098981193006
Publisher Site
http://dx.doi.org/10.1016/j.cca.2019.02.016DOI Listing
February 2019
4 Reads

Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients.

Expert Rev Qual Life Cancer Care 2018 26;3(1):19-26. Epub 2018 Feb 26.

Department of Neurology, Department of Neurological Surgery, and Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.

Introduction: chemotherapy-related cognitive dysfunction (CRCD) is a growing problem due to rising cancer rates and increasing numbers of cancer survivors. upwards of 70% of ovarian cancer patients report cognitive-changes following treatment for their cancer.

Areas Covered: the underlying mechanisms of CRCD are a subject of active research and debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23809000.2018.1443811DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377208PMC
February 2018

Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression.

Oncotarget 2019 Jan 18;10(6):673-683. Epub 2019 Jan 18.

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, 5650871, Japan.

Paclitaxel is a first-line drug for treating epithelial ovarian cancer (EOC). However, prognosis for patients with advanced stage cancer remains poor due to primary or acquired drug resistance. Therefore, overcoming chemoresistance is one of the greatest challenges in treating EOC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26586DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363016PMC
January 2019

SERS-based detection of haptoglobin in ovarian cyst fluid as a point-of-care diagnostic assay for epithelial ovarian cancer.

Cancer Manag Res 2019 31;11:1115-1124. Epub 2019 Jan 31.

Laboratory of Bio-optical Imaging, Singapore Bioimaging Consortium, Agency for Science Technology and Research (ASTAR), Singapore,

Purpose: To evaluate haptoglobin (Hp) in ovarian cyst fluid as a diagnostic biomarker for epithelial ovarian cancers (EOCs) using surface-enhanced Raman spectroscopy (SERS)-based in vitro diagnostic assay for use in an intraoperative setting.

Methods: SERS-based method was used to detect and quantify Hp in archived ovarian cyst fluids collected from suspicious ovarian cysts and differentiate benign tumors from EOCs. The diagnostic performance of SERS-based assay was verified against the histopathology conclusions and compared with the results of CA125 test and frozen sections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S185375DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362937PMC
January 2019

Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.

Gynecol Oncol 2019 Feb 13. Epub 2019 Feb 13.

CoRPS - Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, the Netherlands; Netherlands Comprehensive Cancer Organisation, the Netherlands.

Objective: To assess long-term differences in health-related quality of life (HRQoL) of older ovarian cancer survivors compared to both an age-matched normative population and to younger survivors. In addition, the differential effect of chemotherapy on HRQoL between older and younger survivors was compared.

Methods: Ovarian cancer survivors (n = 348) diagnosed between 2000 and 2010, as registered by the Dutch population-based Eindhoven Cancer Registry, were invited to complete the EORTC QLQ-C30 HRQoL questionnaire in 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.001DOI Listing
February 2019
1 Read

Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer.

Int J Clin Oncol 2019 Feb 15. Epub 2019 Feb 15.

Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, Truma-cho 65, Showa-ku, 466-8550, Nagoya, Japan.

Background: Fertility-sparing surgery (FSS) has mainly been chosen for young women with ovarian-confined/well-differentiated epithelial ovarian cancer (EOC). In general, FSS consists of at least conservation of contralateral ovary and the uterus with a staging surgery. However, information on the clinical outcome in women who underwent cystectomy as a fertility-preserving option is lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01416-yDOI Listing
February 2019

RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.

FASEB J 2019 Feb 15:fj201801529RR. Epub 2019 Feb 15.

Department of Gynecology, People's Hospital of Huadu District, Guangzhou, China.

Currently, cisplatin (DDP) is the first-line chemotherapeutic agent used for treatment of ovarian cancer, but gradually acquired drug resistance minimizes its therapeutic outcomes. We aimed to identify crucial genes associated with DDP resistance in ovarian cancer and uncover potential mechanisms. Two sets of gene expression data were downloaded from Gene Expression Omnibus, and bioinformatics analysis was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.201801529RRDOI Listing
February 2019
1 Read

Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance.

Cancer Med 2019 Feb 13. Epub 2019 Feb 13.

Department of Oncology, Division of Gynecologic Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan.

Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1944DOI Listing
February 2019
1 Read

High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis.

Arch Gynecol Obstet 2019 Feb 13. Epub 2019 Feb 13.

Department of Obstetrics and Gynecology, The Affiliated Chencun Hospital of Shunde Hospital of Southern Medical University, Shunde, 528300, Guangdong, People's Republic of China.

Objective: The prognostic significance of Ki-67 expression in patients with ovarian cancer was controversial in various studies. Therefore, we carried out a meta-analysis to determine the prognostic significance of Ki-67 in ovarian cancer patients.

Methods: We searched PubMed, Cochrane Library, EMBASE, Web of Knowledge, China National Knowledge Infrastructure database and WanFang digital database for eligible studies from January 1, 1990 to June 1, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05082-3DOI Listing
February 2019
1 Read

Microvesicle Proteomic profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection.

Mol Cell Proteomics 2019 Feb 13. Epub 2019 Feb 13.

Sheba Cancer Research Center, Chaim Sheba Medical Center, Israel.

High-grade ovarian cancer (HGOC) is the leading cause of mortality from gynecological malignancies, due to diagnosis at a metastatic stage. Current screening options fail to improve mortality due to the absence of early-stage-specific biomarkers. We postulated that a liquid biopsy, such as utero-tubal lavage (UtL), may identify localized lesions better than systemic approaches of serum/plasma analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.RA119.001362DOI Listing
February 2019
1 Read

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

Gynecol Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Gynaecology and Gynaecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany; Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

Objective: Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.

Methods: The AGO-CaRE-1 study multicenter database was used for analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.007DOI Listing
February 2019
1 Read

Peroxiredoxin-5 is a negative survival predictor in ovarian cancer.

Ginekol Pol 2019 ;90(1):1-6

Department of Immunology, Center for Biostructure Research, Medical University of Warsaw, Poland.

Objectives: Peroxiredoxins (PRDXs) constitute a family of antioxidant enzymes which are also involved in the process of carcinogenesis. They are composed of six identified isoforms (PRDX-1-6) and are supposed to play different roles in tumor progression, depending on type of cancer and member of the PRDX family. The aim of the study was to assess the prog- nostic value of PRDXs in ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/GP.2019.0001DOI Listing
January 2019
1 Read

Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.

Nat Commun 2019 Feb 12;10(1):716. Epub 2019 Feb 12.

School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.

Copy number loss of PIK3R1 (p85α) most commonly occurs in ovarian cancer among all cancer types. Here we report that ovarian cancer cells manifest a spectrum of tumorigenic phenotypes upon knockdown of PIK3R1. PIK3R1 loss activates AKT and p110-independent JAK2/STAT3 signaling through inducing changes in the phosphorylation of the docking protein Gab2, thereby relieving the negative inhibition on AKT and promoting the assembly of JAK2/STAT3 signalosome, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-08574-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372715PMC
February 2019
10.742 Impact Factor

Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

Ann Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Medical Oncology, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, USA.

Background: Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase 2 study, combination cediranib/olaparib improved progression-free survival (PFS) compared to olaparib alone in relapsed platinum-sensitive ovarian cancer. This updated analysis was conducted to characterize overall survival (OS) and update PFS outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz018DOI Listing
February 2019

Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.

J Gynecol Oncol 2018 Nov 22. Epub 2018 Nov 22.

Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.

Objective: Poly (ADP-ribose) polymerase (PARP) is an important molecule in the early stress response of DNA damage, which is involved in DNA damage repair and cellular senescence. Olaparib, as PARP inhibitor, has an anti-tumor effect on high grade serous ovarian cancer, but its effects on cellular senescence have not been reported. This study intends to explore the role of olaparib in the regulation of senescence in ovarian cancer cells. Read More

View Article

Download full-text PDF

Source
https://ejgo.org/DOIx.php?id=10.3802/jgo.2019.30.e26
Publisher Site
http://dx.doi.org/10.3802/jgo.2019.30.e26DOI Listing
November 2018
2 Reads

Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors.

J Gynecol Oncol 2018 Nov 12. Epub 2018 Nov 12.

Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.

Objective: To investigate the role of adjuvant chemotherapy (CT) in the management of ovarian non-granulosa cell (GC) sex cord-stromal tumors (SCSTs).

Methods: The National Cancer Database was accessed and patients diagnosed between 2004 and 2013 with a malignant non-GC SCST were selected. Overall survival (OS) was evaluated with Kaplan-Meier curves and compared with the log-rank test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3802/jgo.2019.30.e19DOI Listing
November 2018

Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.

Biochem Biophys Res Commun 2019 Mar 7;510(4):580-586. Epub 2019 Feb 7.

The First Clinical College, Hubei University of Chinese Medicine, Wuhan, Hubei, China. Electronic address:

The essential roles of eukaryotic translation initiation factor 4E (eIF4E) have been shown in various cancers, including ovarian cancer. In this work, we demonstrate that eIF4E inhibition in ovarian cancer can be achieved by ribavirin, a FDA-approved antiviral drug. We show that ribavirin at clinically relevant doses significantly inhibits growth and survival in multiple ovarian cancer cell lines, regardless of morphological and molecular subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.01.117DOI Listing
March 2019
1 Read

Perioperative outcomes of extensive bowel resection during cytoreductive surgery in patients with advanced ovarian cancer.

J Surg Oncol 2019 Feb 8. Epub 2019 Feb 8.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea.

Background And Objectives: To achieve optimal cytoreduction, extensive bowel resections are sometimes required in patients with advanced ovarian cancer. Few studies have focused on the extent or number of resections of bowel surgeries and their feasibility.

Methods: We retrospectively reviewed the medical records of patients with advanced ovarian cancer who underwent bowel surgery as part of debulking procedures at Ajou University Hospital from 2006 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25403DOI Listing
February 2019
1 Read
3.244 Impact Factor

Bevacizumab Plus Direct Oral Anticoagulant Therapy in Ovarian Cancer Patients with Distal Deep Vein Thrombosis.

Clin Drug Investig 2019 Feb 8. Epub 2019 Feb 8.

Department of Obstetrics and Gynecology, Toho University Faculty of Medicine, 6-11-1 Omorinishi, Ota-ku, Tokyo, 143-8541, Japan.

Background And Objective: Administration of bevacizumab to ovarian cancer patients with distal deep vein thrombosis (DVT) is problematic because of lack of evidence about the likely outcomes. We conducted a preliminary study in ovarian cancer patients with DVT who received bevacizumab combined with a direct oral anticoagulant (DOAC).

Methods: We retrospectively investigated patients with advanced or recurrent epithelial ovarian cancer and distal DVT diagnosed by ultrasonography who underwent chemotherapy containing bevacizumab (15 mg/kg every 3 weeks) combined with DOAC therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40261-019-00757-wDOI Listing
February 2019
1 Read

Multiple primary cancers associated with endometrial and ovarian cancers: An analysis based upon the Japan Autopsy Annual Database from 2002 to 2010.

J Obstet Gynaecol Res 2019 Feb 7. Epub 2019 Feb 7.

Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science (IRIDeS), Tohoku University, Sendai, Japan.

Aim: A thorough analysis of multiple primary cancers (MPC) could provide important information as to the pathogenesis of human malignancies. Analysis of MPC using clinical databases has been performed, but little has been done using autopsy cases. Therefore, in this study, we first retrospectively analyzed MPC associated with endometrial and ovarian cancers using the Japan Autopsy Annual Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jog.13934DOI Listing
February 2019
1 Read

Suprarenal lymph node dissection by the Kocher maneuver in the surgical management of ovarian cancer.

Int J Gynecol Cancer 2019 Feb 7. Epub 2019 Feb 7.

Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2018-000093DOI Listing
February 2019
1 Read

Evaluation of trace elements associated with antioxidant enzymes in blood of primary epithelial ovarian cancer patients.

J Trace Elem Med Biol 2019 Mar 16;52:254-262. Epub 2019 Jan 16.

Hacettepe University, Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara 06100, Turkey. Electronic address:

Epithelial ovarian cancer (EOC) has been associated with oxidative stress (OS) due to epithelial inflammation which makes ovaries more vulnerable to the deleterious effects of reactive oxygen species (ROS). However, antioxidant enzymes (AOEs) such as manganese-superoxide dismutase (Mn-SOD), copper,zinc-superoxide dismutase (Cu,Zn-SOD) and glutathione peroxidase (GPx1) protect cells against the biological damage of ROS-induced OS and support cancer prevention by maintaining normal cell cycle progression, inhibiting proliferation, tumor invasion, angiogenesis, inflammation or inducing apoptosis. In the present study, we aimed to measure the levels of trace elements [manganese (Mn), copper (Cu), zinc (Zn) and selenium (Se)] which are structurally and/or functionally associated with the AOEs by inductively coupled plasma/mass-spectrometry (ICP/MS) in blood samples of patients with EOC (M, n = 26) and compare the data with healthy subjects (C, n = 46). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtemb.2019.01.010DOI Listing
March 2019
1 Read

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.

FASEB J 2019 Feb 6:fj201801789RR. Epub 2019 Feb 6.

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Despite surgical and chemotherapeutic advances over the past few decades, the prognosis for ovarian cancer remains very poor. Although cyclin-dependent kinase (CDK) 9 has an established pathogenic role in various cancers, its function in ovarian cancer remains poorly defined. The purpose of this study was to evaluate the expression of CDK9 and its therapeutic potential in ovarian cancer. Read More

View Article

Download full-text PDF

Source
https://www.fasebj.org/doi/10.1096/fj.201801789RR
Publisher Site
http://dx.doi.org/10.1096/fj.201801789RRDOI Listing
February 2019
6 Reads

Gynecologic cancers and solid organ transplantation.

Am J Transplant 2019 Feb 6. Epub 2019 Feb 6.

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Solid organ transplant (SOT) recipients have approximately 2-fold greater risk of developing and dying from a malignancy compared to the general population. Among the gynecologic cancers, including uterine, cervical, vaginal, vulvar, and ovarian, the HPV-related cancers are known to increase among women post-transplantation compared to women in the general population, but less is known about the risk of uterine and ovarian cancers. This review will provide an overview of the epidemiology of gynecologic cancers after SOT, as well as their pathophysiology, management, and specific risk factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15292DOI Listing
February 2019
2 Reads

Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.

Breast Cancer 2019 Feb 6. Epub 2019 Feb 6.

Department of Laboratory Medicine, College of Medicine, Ewha Womans University, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul, 07985, Republic of Korea.

Background: Although BRCA1 or BRCA2 (BRCA1/2) genetic testing plays an important role in determining treatment modalities in patients with hereditary breast and ovarian cancer, sequence variants with unknown clinical significance or variant of uncertain significance (VUS) have limited use in medical decision-making. With vast quantities of gene-related data being updated, the clinical significance of VUS may change over time. We reinterpreted the sequence variant previously reported as BRCA1/2 VUS results in patients with breast or ovarian cancer and assessed whether the clinical significance of VUS was changed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00951-wDOI Listing
February 2019

A case of ovarian endometrioid adenocarcinoma with yolk sac differentiation and Lynch syndrome.

Gynecol Oncol Rep 2019 Feb 11;27:60-64. Epub 2019 Jan 11.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, MD Anderson Cancer Center at Cooper, Cooper University Health System, Camden, NJ, USA.

Ovarian endometrioid adenocarcinoma with yolk sac component has been reported in fewer than twenty cases in the literature. A majority of the diagnoses are described in postmenopausal women without specific reference to germline genetic testing. We describe, to our knowledge, the first case in the English literature of a premenopausal woman that presented with an ovarian endometrioid adenocarcinoma with focal yolk sac component and was subsequently found to have a germline mutation confirming a diagnosis of Lynch syndrome. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525789193000
Publisher Site
http://dx.doi.org/10.1016/j.gore.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348978PMC
February 2019
2 Reads

Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced stage epithelial ovarian cancer.

J BUON 2018 12;23(7):111-115

Baskent University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey.

Purpose: To identify the significance of the number of neoadjuvant chemotherapy (NACT) cycles on pathologic response and to define relationship between multiple cycles of NACT and the timing of interval debulking surgery (IDS) in epithelial ovarian cancer (EOC) patients.

Methods: This retrospective case-control study was carried out at the Baskent University in Ankara between 2007 and 2017. We reviewed 62 patients with advanced stage (IIIC-IV) EOC who received NACT in other institutes and operated in our clinic. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer.

J Cancer 2019 1;10(2):397-407. Epub 2019 Jan 1.

Center of Reproduction and Genetics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215002, China.

Primary platinum-based chemoresistance occurs in approximately one-third of patients with serous ovarian cancer (SOC); however, traditional clinical indicators are poor predictors of chemoresistance. So we aimed to identify novel genes as predictors of primary platinum-based chemoresistance. Gene expression microarray analyses were performed to identify the genes related to primary platinum resistance in SOC on two discovery datasets (GSE51373, GSE63885) and one validation dataset (TCGA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.28127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360311PMC
January 2019
2 Reads

A multifunctional-targeted nanoagent for dual-mode image-guided therapeutic effects on ovarian cancer cells.

Int J Nanomedicine 2019 21;14:753-769. Epub 2019 Jan 21.

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China,

Purpose: Nanomedicine has emerged as a novel therapeutic modality for cancer treatment and diagnosis. Lipid-polymer hybrid nanoparticles (LPHNPs) are core-shell nanoparticle (NP) structures comprising polymer cores and lipid shells, which exhibit complementary characteristics of both polymeric NPs and liposomes. However, it is difficult to wrap perfluoropentane (PFP) into core-shell NPs in the existing preparation process, which limits its application in the integration of diagnosis and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S187929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345190PMC
January 2019
1 Read

Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.

Int J Gynecol Cancer 2019 Feb 4;29(2):334-340. Epub 2019 Jan 4.

Department of Obstetrics and Gynecology, Women's Cancer Center, Yonsei cancer Center, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.

Objective: The aim of this study is to analyze the long-term relapse-free survival and overall survival outcomes of primary ovarian cancer patients using adenosine triphosphate-based chemotherapy response analysis.

Methods: In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed. Chemosensitivity with single or combined three agents and clinical characteristics of patients were studied to understand their correlation with long-term relapse-free survival and overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2018-000058DOI Listing
February 2019
1.949 Impact Factor

Pre-operative evaluation in advanced ovarian cancer: is ultrasound ready to replace computed tomography?

Authors:
Debora Verri

Int J Gynecol Cancer 2019 Feb;29(2):225-226

Department of Obstetrics and Gynecology, Presidio Ospedaliero Alessandro Manzoni, Lecco 23900, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2018-000186DOI Listing
February 2019

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.

Gynecol Oncol 2019 Feb 1. Epub 2019 Feb 1.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, United States of America; Duke Cancer Institute, United States of America. Electronic address:

Objectives: A recent randomized controlled trial demonstrated an overall survival benefit to the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to neoadjuvant chemotherapy (NACT) for stage III epithelial ovarian cancer (EOC). The objective of the current study was to quantify the cost-effectiveness of HIPEC in this setting.

Methods: A decision analytic cost-effectiveness model was designed from a payer perspective to compare 2 surgical management strategies for EOC: (1) interval cytoreductive surgery (ICS); (2) ICS + HIPEC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.025DOI Listing
February 2019

The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer.

J Ovarian Res 2019 Feb 4;12(1):12. Epub 2019 Feb 4.

Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.

Background: The aim of this study was to (1) evaluate the ability of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) parameters to predict suboptimal cytoreduction and (2) to create a risk model for predicting suboptimal cytoreduction in advanced ovarian cancer. From 2011 to 2015, 51 patients underwent primary cytoreductive surgery for advanced ovarian cancer were enrolled. A residual disease with maximal diameter >  1 cm was considered a suboptimal surgical result. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-019-0488-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360666PMC
February 2019

Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer.

Oncoimmunology 2019 16;8(2):e1535730. Epub 2018 Nov 16.

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Suppression of immune reactivity by increased expression of co-inhibitory receptors has been discussed as a major reason as to why the immune system fails to control tumor development. Elucidating the co-inhibitory expression pattern of tumor-infiltrating lymphocytes in different cancer types will help to develop future treatment strategies. We characterized markers reflecting and affecting T-cell functionality by flow cytometry on lymphocytes isolated from blood, ascites and tumor from advanced ovarian cancer patients (n = 35). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1
Publisher Site
http://dx.doi.org/10.1080/2162402X.2018.1535730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343785PMC
November 2018
2 Reads

SPSB1 enhances ovarian cancer cell survival by destabilizing p21.

Biochem Biophys Res Commun 2019 Mar 31;510(3):364-369. Epub 2019 Jan 31.

Department of Obstetrics and Gynecology, College of Medicine, Ewha Womans University, Seoul, South Korea; Innovative Research Center for Control and Prevention of Women's Cancer, Ewha Womans University Mokdong Hospital, Seoul, South Korea. Electronic address:

SPRY domain-containing SOCS box protein 1 (SPSB1) is an E3 ligase adaptor protein with unknown functions in cancer cells. In this study, we found that SPSB1 knockdown markedly decreased the viability and migration of ovarian cancer cells, while ectopic SPSB1 overexpression in IL-3-dependent Ba/F3 cells significantly increased their proliferation rate compared with empty vector-transfected cells. SPSB1 knockdown significantly elevated p21 protein and mRNA levels and induced apoptosis in ovarian cancer cells, as evidenced by increased levels of cleaved PARP and decreased levels of Bcl-2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.01.088DOI Listing

Association of hCG and LHCGR expression patterns with clinicopathological parameters in ovarian cancer.

Pathol Res Pract 2019 Jan 19. Epub 2019 Jan 19.

Department of Obstetrics and Gynecology; Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China. Electronic address:

In addition to its critical role during pregnancy, human chorionic gonadotropin (hCG) has been shown to be expressed by various tumor types. Recent studies have similarly documented the presence of the luteinizing hormone (LH)/hCG receptor (LHCGR) in a variety of nongonadal organs; however, its clinicopathological significance in ovarian cancer remains unclear. The present study used a combination of immunohistochemical, real-time PCR, and western blot analyses to examine hCG and LHCGR expression in normal and cancerous tissues collected from patients with epithelial ovarian cancer (EOC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.01.001DOI Listing
January 2019
1.562 Impact Factor

Univariate and classification analysis reveals potential diagnostic biomarkers for early stage ovarian cancer Type 1 and Type 2.

J Proteomics 2019 Mar 30;196:57-68. Epub 2019 Jan 30.

Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden. Electronic address:

Biomarkers for early detection of ovarian tumors are urgently needed. Tumors of the ovary grow within cysts and most are benign. Surgical sampling is the only way to ensure accurate diagnosis, but often leads to morbidity and loss of female hormones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jprot.2019.01.017DOI Listing
March 2019
2 Reads

Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.

J Exp Med 2019 Feb 1. Epub 2019 Feb 1.

Department of Gynecological Oncology & Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, TX.

High-grade serous ovarian cancer (HGSOC) is hallmarked by early onset of peritoneal dissemination, which distinguishes it from low-grade serous ovarian cancer (LGSOC). Here, we describe the aggressive nature of HGSOC ascitic tumor cells (ATCs) characterized by integrin α5 (ITGA5) ATCs, which are prone to forming heterotypic spheroids with fibroblasts. We term these aggregates as metastatic units (MUs) in HGSOC for their advantageous metastatic capacity and active involvement in early peritoneal dissemination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20180765DOI Listing
February 2019
1 Read

Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?

Gynecol Oncol 2019 02;152(2):221-222

Department of Obstetrics and Gynecology and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.005DOI Listing
February 2019
3.774 Impact Factor

Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study).

Medicine (Baltimore) 2019 Feb;98(5):e14290

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute of Molecular Life Sciences, Nijmegen, The Netherlands.

Introduction: Recurrent ovarian carcinoma has dismal prognosis, but control of disease and prolonged survival are possible in some patients. The estimated 5-year survival is 46% for all stages of ovarian cancer, and only 28% for metastasized disease. Notably, the majority of women with ovarian cancer are diagnosed with stage III or IV disease with a high recurrence rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014290DOI Listing
February 2019
1 Read

PD-L1 disruption by CRISPR/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.

Cancer Sci 2019 Jan 31. Epub 2019 Jan 31.

Department of Obstetrics and Gynecology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.

Programmed cell death ligand 1 (PD-L1) on tumor cells suppresses anti-tumor immunity and has an unfavorable prognostic impact in ovarian cancer patients. We herein report the pathophysiological and therapeutic impacts of PD-L1 disruption in ovarian cancer. PD-L1 was genetically disrupted in the murine ovarian cancer cell line ID8 using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated genome editing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13958DOI Listing
January 2019
2 Reads

SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.

J Cell Biochem 2019 Jan 30. Epub 2019 Jan 30.

Department of Obstetrics and Gynecology, Peking University Frist Hospital, Beijing, China.

Objective: To figure out the relationship between SMAD3 and serine-threonine tyrosine kinase (STYK1) in ovarian carcinoma cell's paclitaxel resistance.

Methods: The quantitative reverse transcription-polymerase chain reactpostion and Western blot analysis were used to analyze RNA and protein content of SMAD3 and STYK1, respectively. The chromatin immunoprecipitation assay was used to confirm the binding site of SMAD3 to the STYK1 promoter region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28371DOI Listing
January 2019
1 Read

Comparison and analysis of the clinicopathological features of SCEO and ECOM.

J Ovarian Res 2019 Jan 30;12(1):10. Epub 2019 Jan 30.

Department of Gynecology, obstetrics and gynecology hospital, Fudan university, Shanghai, 200,090, China.

Objective: The aim of our study was to evaluate and compare the differences in the clinicopathological variables and overall survival (OS) of synchronous primary cancers of the endometrium and ovary (SCEO) and endometrial cancer with ovarian metastasis (ECOM). In addition, we aimed to determine the characteristics of and effective treatments for patients with SCEO to avoid misdiagnosis and overtreatment.

Materials And Methods: A review of medical records from January 2009 to January 2017 revealed 111 patients with coexisting ovarian and endometrial carcinoma diagnosed at the Obstetrics and Gynecology Hospital of Fudan University. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-019-0485-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352368PMC
January 2019
1 Read

Abundance of mitochondrial superoxide dismutase is a negative predictive biomarker for endometriosis-associated ovarian cancers.

World J Surg Oncol 2019 Jan 30;17(1):24. Epub 2019 Jan 30.

Department of Obstetrics and Gynecology, Shiga University of Medical Science, SetaTsukinowa-cho, Otsu, Shiga, 520-2192, Japan.

Background: Endometrioid ovarian carcinoma and clear cell ovarian carcinoma are both classified as endometriosis-associated ovarian cancers (EAOCs). Despite the high rates of recurrence and mortality of EAOC, only a few prognostic biomarkers have been reported. Mitochondrial superoxide dismutase (SOD2) plays an important role in maintaining mitochondrial function through oxidative stress tolerance and contributes to chemotherapeutic resistance. Read More

View Article

Download full-text PDF

Source
https://wjso.biomedcentral.com/articles/10.1186/s12957-019-1
Publisher Site
http://dx.doi.org/10.1186/s12957-019-1565-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354361PMC
January 2019
2 Reads

Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer.

Int J Gynaecol Obstet 2019 Jan 30. Epub 2019 Jan 30.

IRCCS Foundation, National Cancer Institute, Milan, Italy.

Objective: To identify predictive factors of recurrence and survival in patients with early-stage epithelial ovarian cancer (eEOC).

Methods: We retrospectively searched the medical records of all women undergoing optimal surgical staging for eEOC (stage I-II) at the National Cancer Institute of Milan, Italy, between January 1, 1974, and December 31, 2014.

Results: During the study period, 429 patients underwent primary surgery followed by either adjuvant chemotherapy or observation alone for apparent eEOC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijgo.12769DOI Listing
January 2019

Changes in health-related quality of life among gynecologic cancer survivors during the two years after initial treatment: a longitudinal analysis.

Acta Oncol 2019 Jan 30:1-11. Epub 2019 Jan 30.

a Netherlands Comprehensive Cancer Organisation , Utrecht , The Netherlands.

Background: While many cancer survivors experience persistent impairments in health-related quality of life (HRQoL) for extended periods of time, others recover soon after treatment. The aim of this research is to assess changes in health-related quality of life in endometrial and ovarian cancer survivors during two years post initial treatment, and to assess clinical and sociodemographic characteristics associated with those changes.

Methods: This prospective population-based cohort study includes longitudinal data of endometrial (N = 221) and ovarian (N = 174) cancer survivors diagnosed between 2011 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2018.1560498DOI Listing
January 2019
1 Read

TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer.

Cancer Manag Res 2019 17;11:839-855. Epub 2019 Jan 17.

Department of Obstetrics and Gynaecology, Shengjing Hospital Affiliated to China Medical University, Liaoning, China,

Background: Transmembrane protein with epidermal growth factor-like and two follistatin-like domains 1 (TMEFF1) has an anticarcinogenic effect in brain tumors. However, little is known about the role of TMEFF1 in epithelial ovarian cancer (EOC).

Materials And Methods: TMEFF1 expression in EOC was detected by immunohistochemistry; its relationship with clinical pathological parameters and its influence on prognosis were analyzed. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/tmeff1-overexpression-and-its-mech
Publisher Site
http://dx.doi.org/10.2147/CMAR.S186080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340504PMC
January 2019
5 Reads